Key Events This Week
1 June: Stock opens at Rs.1,684.00, Sensex down 0.96%
2 June: Mojo Grade downgraded to Sell; stock closes at Rs.1,698.25 (+0.85%)
3 June: Technical momentum shifts to sideways; stock dips slightly to Rs.1,696.85 (-0.08%)
5 June: Stock rallies to Rs.1,722.75 (+1.22%) despite Sensex decline
1 June 2026: Modest Start Amid Broad Market Weakness
Corona Remedies began the week at Rs.1,684.00, gaining 0.57% on the day, while the Sensex fell sharply by 0.96% to 35,077.62. The stock’s resilience in the face of broader market weakness suggested underlying investor interest, supported by a relatively low volume of 6,263 shares traded. This set a cautiously optimistic tone for the week ahead.
2 June 2026: Downgrade to Sell Dampens Sentiment but Price Advances
On 2 June, MarketsMOJO downgraded Corona Remedies Ltd from a Hold to a Sell rating, citing deteriorating technical indicators, flat quarterly financial results, and stretched valuation metrics. The Mojo Score was revised to 48.0, firmly placing the stock in the Sell category. Despite this negative development, the stock closed higher at Rs.1,698.25, up 0.85% on the day, outperforming the Sensex which rose 0.43% to 35,227.64.
The downgrade reflected concerns over a shift in technical momentum from mildly bullish to sideways, with key indicators such as MACD and RSI showing no clear directional signals. Financially, the company reported a 15.8% decline in quarterly profit before tax less other income, signalling stagnation in earnings growth. Valuation remained a concern with an EV/CE ratio of 12, suggesting the stock trades at a premium relative to its capital employed.
Momentum building strong! This Mid Cap from NBFC is on our MomentumNow radar. Other investors are catching on – will you join?
- - Building momentum strength
- - Investor interest growing
- - Limited time advantage
3 June 2026: Technical Momentum Shifts to Sideways Amid Mixed Signals
The following day, Corona Remedies experienced a slight decline of 0.08%, closing at Rs.1,696.85. Technical analysis revealed a shift from a mildly bullish trend to a sideways pattern, indicating a pause in upward momentum. Key momentum indicators such as MACD and RSI remained inconclusive, while the On-Balance Volume (OBV) showed a mildly bearish signal on the weekly chart.
The stock traded within a range of Rs.1,664.80 to Rs.1,719.00, staying well above its 52-week low of Rs.1,336.95 but below the 52-week high of Rs.1,951.30. This price action reflected investor indecision amid mixed market signals. The weekly Bollinger Bands remained bullish, suggesting contained volatility and potential for a future breakout, but the lack of clear directional cues warranted caution.
4 June 2026: Modest Recovery as Market Shows Slight Strength
On 4 June, Corona Remedies edged up by 0.30% to close at Rs.1,701.95, supported by a modest increase in the Sensex (+0.19%). Trading volume remained subdued at 474 shares, consistent with the consolidation phase. The stock’s ability to maintain gains despite technical uncertainties indicated underlying support, though momentum remained muted.
Holding Corona Remedies Ltd from ? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
5 June 2026: Strong Finish Despite Market Decline
Corona Remedies closed the week on a strong note, gaining 1.22% to Rs.1,722.75, its highest close of the week. This rally occurred despite the Sensex declining by 0.10% to 35,141.95, highlighting the stock’s relative strength. Trading volume increased to 801 shares, signalling renewed investor interest. The stock’s resilience amid a broadly negative market environment underscored its year-to-date outperformance of 22.54%, well ahead of the Sensex’s 12.40% decline.
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-06-01 | Rs.1,684.00 | +0.57% | 35,077.62 | -0.96% |
| 2026-06-02 | Rs.1,698.25 | +0.85% | 35,227.64 | +0.43% |
| 2026-06-03 | Rs.1,696.85 | -0.08% | 35,107.33 | -0.34% |
| 2026-06-04 | Rs.1,701.95 | +0.30% | 35,175.61 | +0.19% |
| 2026-06-05 | Rs.1,722.75 | +1.22% | 35,141.95 | -0.10% |
Key Takeaways
Positive Signals: Corona Remedies outperformed the Sensex by 3.66% during the week, closing at a weekly high of Rs.1,722.75. The company remains net-debt free with strong management efficiency and a robust Return on Capital Employed (29.5%). Institutional investors increased their stake to 9.26%, reflecting confidence in long-term fundamentals.
Cautionary Signals: The downgrade to a Sell rating by MarketsMOJO on 2 June highlights concerns over flat quarterly financial performance and stretched valuation metrics, with an EV/CE ratio of 12. Technical momentum shifted to sideways, with mixed signals from MACD, RSI, and OBV indicators, suggesting a consolidation phase and limited near-term directional clarity.
Conclusion
Corona Remedies Ltd’s week was characterised by a blend of resilience and caution. The stock’s 2.88% weekly gain and outperformance against the Sensex underscore its relative strength amid a challenging market backdrop. However, the downgrade to a Sell rating and the sideways technical momentum signal a need for prudence. Investors should closely monitor upcoming quarterly results and technical developments to gauge whether the stock can regain bullish momentum or face further consolidation. For now, Corona Remedies remains a stock with strong long-term fundamentals but mixed near-term signals that warrant careful analysis.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
